Conference Track

Metastatic Breast Cancer

Source: CCO Independent Conference Coverage of the 2008 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Improved TTP With Addition of Pegylated Liposomal Doxorubicin to Docetaxel in Anthracycline-Pretreated Advanced Breast Cancer Patients
Continuing Bevacizumab After Docetaxel Discontinuation Delays Disease Progression and Death in Patients With HER2-Negative Locally Recurrent or Metastatic Breast Cancer
Vorinostat Plus Paclitaxel and Bevacizumab Shown Safe and Effective in Previously Untreated Metastatic Breast Cancer Patients
Everolimus in Combination With Vinorelbine and Trastuzumab Feasible Treatment Option in Metastatic Breast Cancer Patients
Temsirolimus Monotherapy Shows Minimal Activity in Heavily Pretreated Patients With Metastatic Breast Cancer
Denosumab Associated with Suppression of Bone Turnover in Breast Cancer Patients With Inadequate Responses to Intravenous Bisphosphonates
Single-Agent Dasatinib Shows Modest Activity in Patients With Advanced Triple-Negative Breast Cancer
Possible Efficacy Benefit With Addition of Gefitinib to Anastrozole in Postmenopausal Women With Hormone Receptor–Positive Metastatic Breast Cancer
Pertuzumab Plus Trastuzumab Synergistic in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
Histopathologic Criteria Insufficient to Predict Presence of Disseminated Tumor Cells to Use as Possible Surrogate Marker in Hormone Receptor–Positive Breast Cancer
High-Dose Fulvestrant Shown as Effective as Anastrozole in Patients With Advanced Breast Cancer
High-Dose Estrogens Show Benefit in Heavily-Treated Patients With MBC
Addition of Gefitinib to Anastrozole Does Not Benefit Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer

Expert Analysis

Metastatic Breast Cancer

Moderator: Richard Finn, MD

Faculty:

Clifford A. Hudis, MD
Kathy D. Miller, MD
Joyce O’Shaughnessy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize recent data on the use of targeted therapies for the treatment of metastatic breast cancer
Discuss new findings on agents used for the prevention and treatment of bone metastases in metastatic breast cancer patients
Describe the use of hormonal therapies for the treatment of metastatic breast cancer

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: February 11, 2009

Expiration Date: February 10, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.